Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 3/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 4/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | CASP1 | P29466 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | GLA | P06280 | 2/20 | 0.32 |
| ▸ | CASP7 | P55210 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16335305 | 0.81 | CYP1A1 (0.39) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL16340262 | 0.80 | ALDH1A1 (0.47) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL19464531 | 0.78 | KDM4E (0.34) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL19464540 | 0.78 | CYP1A1 (0.37) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL16339662 | 0.77 | KDM4E (0.39) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL17762891 | 0.76 | CYP1A1 (0.35) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL17762896 | 0.76 | KDM4E (0.32) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL16340064 | 0.76 | KDM4E (0.50) | KDM4EALDH1A1GAAHPGDCASP1 | |
| SCHEMBL17746848 | 0.75 | KDM4E (0.30) | KDM4EALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL17746832 | 0.73 | CYP1A1 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790231-B2 | Chromane and chromene derivatives and their use as CRAC modulators | LUPIN LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-9790231-B2 | Chromane and chromene derivatives and their use as CRAC modulators | LUPIN LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-19 | — | — | US | disclosed |
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2016-05-19 | — | — | US | disclosed |
| EP-3013810-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | Lupin Limited (IN) | 2016-05-04 | — | — | EP | disclosed |
| WO-2014207648-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014207648-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | LUPIN LIMITED (IN) | 2014-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137659-A1 | CHROMANE AND CHROMENE DERIVATIVES AND THEIR USE AS CRAC MODULATORS | ORAI1, RYR2, RYR1 | KDM4E 3112/4885ALDH1A1 2782/4885NPC1 921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.